Enliven Therapeutics, Inc.
No enriched coverage for $ELVN in the last 7 days.
No SEC Form 4 filings for $ELVN in the last 30 days.
Enliven Therapeutics (ELVN) has announced updates to its board of directors as it prepares for its next phase of development. The article highlights recent analyst ratings for ELVN and lists related SEC filings and insider trading activity, underscoring the company's recent corporate and financial news. This information is sourced from Quantisnow, a real-time market data platform.
Joseph Lyssikatos, an insider at Enliven Therapeutics (NASDAQ:ELVN), sold 20,000 shares of the company's stock for $535,000 on January 20th, reducing his holding by 2.61%. Following the sale, Lyssikatos directly owns 745,188 shares, valued at approximately $19.93 million. Enliven Therapeutics is trading down 0.6%, with a market cap of $1.60 billion, and analysts maintain a "Moderate Buy" rating with an average target price of $41.00.
The mean of analysts' price targets for Enliven Therapeutics, Inc. (ELVN) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
